Loading...
Loading...
- Incyte Corporation's INCY Q3 adjusted EPS reached $1.18, compared to $0.23 posted a year ago, beating the consensus of $0.73.
- Sales increased 31% Y/Y to $812.99 million, ahead of the consensus of $738.77 million.
- Related Link: Syndax Pharma, Incyte Ink Licensing Pact For Graft Vs. Host Disease Candidate.
- The Company reported an operating income of $235.4 million, compared to $5.32 million posted a year ago.
- Product and royalty revenues increased 25% Y/Y to $777.98 million, driven by Jakafi, Iclusig, and Pemazyre net product revenues and higher product royalty revenues from Jakavi, Olumiant, and Tabrecta.
- The 202% growth in Olumiant royalty revenues reflects an increase in net product sales due to the use of Olumiant for COVID-19.
- Cash, cash equivalents, and marketable securities totaled $2.3 billion.
- Guidance: Incyte reaffirmed FY21 Jakafi net product revenues at $2.125 billion - $2.170 billion
- Related: Incyte's Parsaclisib Application Under FDA Review For 3 Types Of Non-Hodgkin Lymphomas.
- Price Action: INCY shares are down 8.39% at $63.50 during the market session on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in